2024
(333) TRENDS IN PHOSPHODIESTERASE TYPE 5 INHIBITOR PRESCRIPTIONS AND COST: MEDICARE ANALYSIS 2017-2021
Cahill E, Reddy S, Rotker K, Honig S. (333) TRENDS IN PHOSPHODIESTERASE TYPE 5 INHIBITOR PRESCRIPTIONS AND COST: MEDICARE ANALYSIS 2017-2021. The Journal Of Sexual Medicine 2024, 21: qdae167.321. DOI: 10.1093/jsxmed/qdae167.321.Peer-Reviewed Original ResearchPhosphodiesterase type 5Non-urologistsPDE5 inhibitorsPhosphodiesterase type 5 inhibitorsMedicare Part D databaseMedicare Part D Public Use FilesCompared urologistsPrescribed tadalafilPrescribed sildenafilSildenafil prescriptionsCost of medicationsErectile dysfunctionInhibitor medicationPrescribing patternsUrologistsPatient comfortPrimary care providersSildenafilTadalafilType 5Direct Application Therapy for Erectile Dysfunction
Heckscher D, Grinnan J, Bieniek J, Honig S. Direct Application Therapy for Erectile Dysfunction. 2024 DOI: 10.1016/b978-0-443-21477-6.00107-3.Peer-Reviewed Original Research
2022
Chapter 4 The impact of erectile dysfunction on infertility and its treatment
Khan A, Lindelof J, Honig S. Chapter 4 The impact of erectile dysfunction on infertility and its treatment. 2022, 57-76. DOI: 10.1016/b978-0-12-822288-1.00008-7.Peer-Reviewed Original Research
2020
Use of Stem Cells in the Treatment of Erectile Dysfunction
Press B, Honig S. Use of Stem Cells in the Treatment of Erectile Dysfunction. 2020, 347-365. DOI: 10.1007/978-3-030-56954-9_16.ChaptersPD28-04 EVALUATION OF ONLINE TELEHEALTH PLATFORMS FOR DIRECT-TO-CONSUMER TREATMENT OF ERECTILE DYSFUNCTION
Hsiang* W, Elftmann E, Honig S, Leapman M. PD28-04 EVALUATION OF ONLINE TELEHEALTH PLATFORMS FOR DIRECT-TO-CONSUMER TREATMENT OF ERECTILE DYSFUNCTION. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000892.04.Peer-Reviewed Original Research
2018
Direct Application Therapy for Erectile Dysfunction
Grinnan J, Bieniek J, Honig S. Direct Application Therapy for Erectile Dysfunction. 2018, 347-352. DOI: 10.1016/b978-0-12-801238-3.64931-0.Peer-Reviewed Original Research
2001
Lecture 3
Berger R, Billups K, Brock G, Broderick G, Dhabuwala C, Goldstein I, Hakim L, Hellstrom W, Honig S, Levine L, Lue T, Munarriz R, Montague D, Mulcahy J, Nehra A, Rogers Z, Rosen R, Seftel A, Shabsigh R, Steers W. Lecture 3. International Journal Of Impotence Research 2001, 13: s39-s43. PMID: 11781746, DOI: 10.1038/sj.ijir.3900777.Peer-Reviewed Original ResearchConceptsPrimary care providersClinical characteristics of painHealth care professionalsCharacteristics of painAssociated psychosocial consequencesModified Delphi methodPeer-reviewed literatureCare providersClinical characteristicsCare professionalsErectile dysfunctionPathophysiological characteristicsPsychosocial consequencesAbsence of painAmerican Foundation for Urologic DiseaseMedical careMultidisciplinary panelClassification of priapismDiagnosis of priapismMulti-institutional trialsMedical conditionsTreatment of priapismClosed compartment syndromeConsequences of delayed treatmentGuidelines Committee